Breast Cancer News

See full report here

"In the press release of Aug 1st, 2014 the Company reported successful silencing of the IDO gene in human dendritic cells (DC) treated with newly developed proprietary gene-silencing technology which was in part licensed from Benitec Biopharma. Today the Company reports that dCellVax generated according to the protocols that will be submitted to the FDA was capable of potently stimulating human T cells to kill breast cancer cells. Combined with animal model efficacy data, GMP-grade manufacturing protocols, and animal safety data, the Company believes it has completed the necessary experimental work to begin writing its IND for a proposed clinical trial in breast cancer patients."

"Immunotherapy offers the possibility of killing tumors by harnessing the power of the immune system. This type of treatment generally lacks the toxicity associated with chemotherapy or radiotherapy and is capable of killing metastatic cells, which usually cause relapse in cancer patients. dCellVax is an immunotherapy using DC generated from breast cancer patients which have been modified so as to lack an enzyme, indolamine 2,3 deoxygenase (IDO) that inhibits the immune response. By lacking this enzyme, the modified DC become potent stimulators of the immune system, a finding which was confirmed by the experiments completed today"